{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:31:39Z","timestamp":1793910699814,"version":"4.8.0"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014472","name":"Scientific Research Foundation of Hunan Provincial Education Department","doi-asserted-by":"publisher","award":["24A0301"],"award-info":[{"award-number":["24A0301"]}],"id":[{"id":"10.13039\/100014472","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.pharmthera.2026.109069","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T17:12:11Z","timestamp":1781457131000},"page":"109069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The CircRNA\/miRNA axis in breast cancer: From molecular mechanisms to clinical translation"],"prefix":"10.1016","volume":"285","author":[{"given":"Huiyu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.pharmthera.2026.109069_bb0005","doi-asserted-by":"crossref","first-page":"7154","DOI":"10.1073\/pnas.1222509110","article-title":"Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environments","volume":"110","author":"Ala","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109069_bb0010","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","article-title":"Liquid biopsy: From discovery to clinical application","volume":"11","author":"Alix-Panabieres","year":"2021","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104535","article-title":"A therapeutic algorithm guiding subsequent therapy selection after CDK4\/6 inhibitors' failure: A review of current and investigational treatment for HR+\/Her2- breast cancer","volume":"204","author":"Astore","year":"2024","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0020","doi-asserted-by":"crossref","first-page":"8057","DOI":"10.1038\/srep08057","article-title":"Correlation of circular RNA abundance with proliferation--exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and normal human tissues","volume":"5","author":"Bachmayr-Heyda","year":"2015","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.plabm.2025.e00470","article-title":"Evaluation of CircHIPK3 biomarker potential in breast cancer","volume":"45","author":"Bahadoran","year":"2025","journal-title":"Practical Laboratory Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109069_bb0030","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109069_bb0035","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.molcel.2014.09.018","article-title":"Endogenous miRNA and target concentrations determine susceptibility to potential ceRNA competition","volume":"56","author":"Bosson","year":"2014","journal-title":"Molecular Cell"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109069_bb0040","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.7150\/thno.24106","article-title":"circEPSTI1 as a prognostic marker and mediator of triple-negative breast cancer progression","volume":"8","author":"Chen","year":"2018","journal-title":"Theranostics"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109069_bb0045","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1002\/jcp.31128","article-title":"CircANKRD17 promotes glycolysis by inhibiting miR-143 in breast cancer cells","volume":"238","author":"Chen","year":"2023","journal-title":"Journal of Cellular Physiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109069_bb0050","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2021.12567","article-title":"CircRNA_0044556 diminishes the sensitivity of triple-negative breast cancer cells to adriamycin by sponging miR-145 and regulating NRAS","volume":"25","author":"Chen","year":"2022","journal-title":"Molecular Medicine Reports"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109069_bb0055","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41580-020-0243-y","article-title":"The expanding regulatory mechanisms and cellular functions of circular RNAs","volume":"21","author":"Chen","year":"2020","journal-title":"Nature Reviews. Molecular Cell Biology"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0060","article-title":"CircWHSC1 promotes breast cancer progression by regulating the FASN\/AMPK\/mTOR axis through sponging miR-195-5p","volume":"11","author":"Chen","year":"2021","journal-title":"Frontiers in Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0065","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s13046-023-02767-1","article-title":"FBXW7 in breast cancer: mechanism of action and therapeutic potential","volume":"42","author":"Chen","year":"2023","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109069_bb0070","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/1759-7714.14310","article-title":"Circ_0001955 plays a carcinogenic role in breast cancer via positively regulating GLUT1 via decoying miR-1299","volume":"13","author":"Cheng","year":"2022","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0075","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/608406","article-title":"Immune microenvironment in tumor progression: characteristics and challenges for therapy","volume":"2012","author":"Chew","year":"2012","journal-title":"Journal of Oncology"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109069_bb0080","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/s41573-022-00521-4","article-title":"Targeting RNA structures with small molecules","volume":"21","author":"Childs-Disney","year":"2022","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"9938","key":"10.1016\/j.pharmthera.2026.109069_bb0085","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.pharmthera.2026.109069_bb0090","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","article-title":"Sacituzumab govitecan in untreated, advanced triple-negative breast cancer","volume":"393","author":"Cortes","year":"2025","journal-title":"The New England Journal of Medicine"},{"issue":"22","key":"10.1016\/j.pharmthera.2026.109069_bb0095","doi-asserted-by":"crossref","first-page":"6741","DOI":"10.1021\/jacs.8b01233","article-title":"Small molecule targeted recruitment of a nuclease to RNA","volume":"140","author":"Costales","year":"2018","journal-title":"Journal of the American Chemical Society"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109069_bb0100","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.molcel.2014.03.045","article-title":"Assessing the ceRNA hypothesis with quantitative measurements of miRNA and target abundance","volume":"54","author":"Denzler","year":"2014","journal-title":"Molecular Cell"},{"issue":"55","key":"10.1016\/j.pharmthera.2026.109069_bb0105","article-title":"Bispecific antibodies targeting mutant RAS neoantigens","volume":"6","author":"Douglass","year":"2021","journal-title":"Science Immunology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0110","doi-asserted-by":"crossref","DOI":"10.1080\/15592294.2025.2482382","article-title":"CircMYH9 promotes the mRNA stability of SPAG6 by recruiting EIF4A3 to facilitate the progression of breast cancer","volume":"20","author":"Fan","year":"2025","journal-title":"Epigenetics"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0115","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.canlet.2019.05.036","article-title":"The circular RNA circ-Ccnb1 dissociates Ccnb1\/Cdk1 complex suppressing cell invasion and tumorigenesis","volume":"459","author":"Fang","year":"2019","journal-title":"Cancer Letters"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109069_bb0120","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death and Differentiation"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2217\/epi-2017-0055","article-title":"Screening circular RNA related to chemotherapeutic resistance in breast cancer","volume":"9","author":"Gao","year":"2017","journal-title":"Epigenomics"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109069_bb0130","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/s41418-024-01396-1","article-title":"127aa encoded by circSpdyA promotes FA synthesis and NK cell repression in breast cancers","volume":"32","author":"Gao","year":"2025","journal-title":"Cell Death and Differentiation"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109069_bb0135","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0140","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41568-020-00306-0","article-title":"RNA in cancer","volume":"21","author":"Goodall","year":"2021","journal-title":"Nature Reviews. Cancer"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109069_bb0145","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10142-023-01083-3","article-title":"Therapeutic and diagnostic applications of exosomal circRNAs in breast cancer","volume":"23","author":"Gopikrishnan","year":"2023","journal-title":"Functional & Integrative Genomics"},{"issue":"27","key":"10.1016\/j.pharmthera.2026.109069_bb0150","article-title":"A circular RNA overcomes acquired resistance to BET inhibitors by antagonizing IGF2BP2-mediated c-MYC translation in TNBC","volume":"122","author":"Guo","year":"2025","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0155","first-page":"4323","article-title":"Expanded identification and characterization of mammalian circular RNAs","volume":"5","author":"Guo","year":"2014","journal-title":"Nature Communications"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109069_bb0160","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"7441","key":"10.1016\/j.pharmthera.2026.109069_bb0165","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature11993","article-title":"Natural RNA circles function as efficient microRNA sponges","volume":"495","author":"Hansen","year":"2013","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.pharmthera.2026.109069_bb0170","doi-asserted-by":"crossref","first-page":"7747","DOI":"10.7150\/thno.112492","article-title":"Smart nanoarchitectures for precision RNA delivery: harnessing endogenous and exogenous stimuli in cancer treatment","volume":"15","author":"Hao","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0175","article-title":"Circular RNA circASS1 is down-regulated in breast cancer cells MDA-MB-231 and suppressed invasion and migration","volume":"11","author":"Hou","year":"2017","journal-title":"Epigenomics"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0180","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.922253","article-title":"Exosomes mediated transfer of Circ_UBE2D2 enhances the resistance of breast cancer to tamoxifen by binding to MiR-200a-3p","volume":"26","author":"Hu","year":"2020","journal-title":"Medical Science Monitor"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109069_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23393","article-title":"Identification of plasma hsa_circ_0008673 expression as a potential biomarker and tumor regulator of breast cancer","volume":"34","author":"Hu","year":"2020","journal-title":"Journal of Clinical Laboratory Analysis"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109069_bb0190","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s12026-021-09237-w","article-title":"Circular RNA hsa_circ_0001598 promotes programmed death-ligand-1-mediated immune escape and trastuzumab resistance via sponging miR-1184 in breast cancer cells","volume":"69","author":"Huang","year":"2021","journal-title":"Immunologic Research"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.105019","article-title":"Trastuzumab deruxtecan: redefining precision oncology across HER2-driven cancers","volume":"217","author":"Jalali","year":"2026","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109069_bb0200","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1261\/rna.035667.112","article-title":"Circular RNAs are abundant, conserved, and associated with ALU repeats","volume":"19","author":"Jeck","year":"2013","journal-title":"RNA"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109069_bb0205","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nrg3853","article-title":"Competition between target sites of regulators shapes post-transcriptional gene regulation","volume":"16","author":"Jens","year":"2015","journal-title":"Nature Reviews. Genetics"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0210","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.molimm.2025.02.014","article-title":"circSTIL mediates pirarubicin inhibiting the malignant phenotype of triple-negative breast cancer and acts as a biomarker in plasma exosomes","volume":"180","author":"Ji","year":"2025","journal-title":"Molecular Immunology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0215","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41420-022-00860-6","article-title":"CircRBM33 downregulation inhibits hypoxia-induced glycolysis and promotes apoptosis of breast cancer cells via a microRNA-542-3p\/HIF-1alpha axis","volume":"8","author":"Jiang","year":"2022","journal-title":"Cell Death Discov"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0220","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13000-020-00963-7","article-title":"Circular RNA KIF4A promotes cell migration, invasion and inhibits apoptosis through miR-152\/ZEB1 axis in breast cancer","volume":"15","author":"Jin","year":"2020","journal-title":"Diagnostic Pathology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109069_bib696","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cell.2015.02.043","article-title":"The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo","volume":"161","author":"Karreth","year":"2015","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109069_bb0225","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1101\/gad.1184704","article-title":"A combined computational-experimental approach predicts human microRNA targets","volume":"18","author":"Kiriakidou","year":"2004","journal-title":"Genes & Development"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109069_bb0230","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41576-019-0158-7","article-title":"The biogenesis, biology and characterization of circular RNAs","volume":"20","author":"Kristensen","year":"2019","journal-title":"Nature Reviews. Genetics"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0235","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1038\/s41467-020-18355-2","article-title":"Spatial expression analyses of the putative oncogene ciRS-7 in cancer reshape the microRNA sponge theory","volume":"11","author":"Kristensen","year":"2020","journal-title":"Nature Communications"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109069_bb0240","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41571-021-00585-y","article-title":"The emerging roles of circRNAs in cancer and oncology","volume":"19","author":"Kristensen","year":"2022","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0245","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12943-024-01990-4","article-title":"Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer","volume":"23","author":"Kundu","year":"2024","journal-title":"Molecular Cancer"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109069_bb0250","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2022.160564","article-title":"Whole transcriptome sequencing and competitive endogenous RNA regulation network construction analysis in benzo[a]pyrene-treated breast cancer cells","volume":"861","author":"Lao","year":"2023","journal-title":"Science of the Total Environment"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0260","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ncrna.2025.08.009","article-title":"NSUN2-mediated m5C hypermethylation of hsa_circ_0004516 promotes breast cancer brain metastasis by activating AKT signaling","volume":"14","author":"Li","year":"2025","journal-title":"Noncoding RNA Res."},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0265","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"Journal of Hematology & Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0270","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ymthe.2021.08.026","article-title":"circ-EIF6 encodes EIF6-224aa to promote TNBC progression via stabilizing MYH9 and activating the Wnt\/beta-catenin pathway","volume":"30","author":"Li","year":"2022","journal-title":"Molecular Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0275","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12943-024-02019-6","article-title":"CircTRIM1 encodes TRIM1-269aa to promote chemoresistance and metastasis of TNBC via enhancing CaM-dependent MARCKS translocation and PI3K\/AKT\/mTOR activation","volume":"23","author":"Li","year":"2024","journal-title":"Molecular Cancer"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109069_bb0280","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41419-023-06006-5","article-title":"circRNA-SFMBT2 orchestrates ERalpha activation to drive tamoxifen resistance in breast cancer cells","volume":"14","author":"Li","year":"2023","journal-title":"Cell Death & Disease"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0285","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12943-020-01152-2","article-title":"Autophagy-associated circRNA circCDYL augments autophagy and promotes breast cancer progression","volume":"19","author":"Liang","year":"2020","journal-title":"Molecular Cancer"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109069_bb0290","first-page":"4337","article-title":"HIF1alpha-associated circDENND4C promotes proliferation of breast cancer cells in hypoxic environment","volume":"37","author":"Liang","year":"2017","journal-title":"Anticancer Research"},{"issue":"42","key":"10.1016\/j.pharmthera.2026.109069_bb0295","doi-asserted-by":"crossref","first-page":"6850","DOI":"10.1038\/s41388-019-0926-z","article-title":"circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p\/PBLD axis in breast cancer","volume":"38","author":"Liang","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0300","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.752651","article-title":"Plasma-derived extracellular vesicles circular RNAs serve as biomarkers for breast cancer diagnosis","volume":"11","author":"Lin","year":"2021","journal-title":"Frontiers in Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0305","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12943-021-01476-7","article-title":"circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer","volume":"21","author":"Ling","year":"2022","journal-title":"Molecular Cancer"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109069_bb0310","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.cell.2022.04.021","article-title":"Circular RNAs: characterization, cellular roles, and applications","volume":"185","author":"Liu","year":"2022","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.pharmthera.2026.109069_bb0315","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1016\/j.molcel.2024.08.020","article-title":"Dynamic conformation: marching toward circular RNA function and application","volume":"84","author":"Liu","year":"2024","journal-title":"Molecular Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0320","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2025.2479926","article-title":"CircATP5C1 promotes triple-negative breast cancer progression by binding IGF2BP2 to modulate CSF-1 secretion","volume":"26","author":"Liu","year":"2025","journal-title":"Cancer Biology & Therapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0325","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1620\/tjem.2023.J039","article-title":"CircRNA CircABCB1 diminishes the sensitivity of breast cancer cells to docetaxel by sponging MiR-153-3p","volume":"261","author":"Liu","year":"2023","journal-title":"The Tohoku Journal of Experimental Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0330","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-017-0630-y","article-title":"Circles reshaping the RNA world: from waste to treasure","volume":"16","author":"Liu","year":"2017","journal-title":"Molecular Cancer"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109069_bb0335","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.tcb.2023.07.009","article-title":"Disulfidptosis: disulfide stress-induced cell death","volume":"34","author":"Liu","year":"2024","journal-title":"Trends in Cell Biology"},{"issue":"14","key":"10.1016\/j.pharmthera.2026.109069_bb0345","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/s41388-021-02061-4","article-title":"Exosomal circCARM1 from spheroids reprograms cell metabolism by regulating PFKFB2 in breast cancer","volume":"41","author":"Liu","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106098","article-title":"Endoplasmic reticulum stress promotes breast cancer cells to release exosomes circ_0001142 and induces M2 polarization of macrophages to regulate tumor progression","volume":"177","author":"Lu","year":"2022","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2023.110690","article-title":"CircKIF4A combines EIF4A3 to stabilize SDC1 expression to activate c-src\/FAK and promotes TNBC progression","volume":"108","author":"Luo","year":"2023","journal-title":"Cellular Signalling"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0360","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13045-021-01052-y","article-title":"Regulatory mechanisms, functions, and clinical significance of CircRNAs in triple-negative breast cancer","volume":"14","author":"Lyu","year":"2021","journal-title":"Journal of Hematology & Oncology"},{"issue":"7441","key":"10.1016\/j.pharmthera.2026.109069_bb0365","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature11928","article-title":"Circular RNAs are a large class of animal RNAs with regulatory potency","volume":"495","author":"Memczak","year":"2013","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109069_bb0370","first-page":"780","article-title":"Screening and validation of lncRNAs and circRNAs as miRNA sponges","volume":"18","author":"Militello","year":"2017","journal-title":"Briefings in Bioinformatics"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109069_bb0375","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","article-title":"The CDK4\/6 inhibitor revolution - a game-changing era for breast cancer treatment","volume":"21","author":"Morrison","year":"2024","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109069_bb0380","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/anie.201912524","article-title":"Responsive exosome nano-bioconjugates for synergistic cancer therapy","volume":"59","author":"Nie","year":"2020","journal-title":"Angewandte Chemie (International Ed. in English)"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109069_bb0385","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24008","article-title":"Serum Circ-FAF1\/Circ-ELP3: a novel potential biomarker for breast cancer diagnosis","volume":"35","author":"Omid-Shafaat","year":"2021","journal-title":"Journal of Clinical Laboratory Analysis"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0390","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13046-025-03355-1","article-title":"CircPVT1 weakens miR-33a-5p unleashing the c-MYC\/GLS1 metabolic axis in breast cancer","volume":"44","author":"Palcau","year":"2025","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109069_bb0395","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.molcel.2015.03.027","article-title":"Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed","volume":"58","author":"Rybak-Wolf","year":"2015","journal-title":"Molecular Cell"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109069_bb0400","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.ymthe.2019.05.011","article-title":"circRNA_0025202 regulates tamoxifen sensitivity and tumor progression via regulating the miR-182-5p\/FOXO3a axis in breast cancer","volume":"27","author":"Sang","year":"2019","journal-title":"Molecular Therapy"},{"issue":"21","key":"10.1016\/j.pharmthera.2026.109069_bb0405","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"The New England Journal of Medicine"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109069_bb0410","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109069_bb0415","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.jmoldx.2024.06.008","article-title":"A network-based framework to discover treatment-response-predicting biomarkers for complex diseases","volume":"26","author":"Shanthamallu","year":"2024","journal-title":"The Journal of Molecular Diagnostics"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109069_bb0420","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s41388-024-02950-4","article-title":"Novel exosomal circEGFR facilitates triple negative breast cancer autophagy via promoting TFEB nuclear trafficking and modulating miR-224-5p\/ATG13\/ULK1 feedback loop","volume":"43","author":"Song","year":"2024","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0425","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12943-023-01806-x","article-title":"A novel polypeptide CAPG-171aa encoded by circCAPG plays a critical role in triple-negative breast cancer","volume":"22","author":"Song","year":"2023","journal-title":"Molecular Cancer"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109069_bb0430","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis","volume":"26","author":"Spring","year":"2020","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2024.116373","article-title":"Simultaneous detection of breast cancer biomarkers circROBO1 and BRCA1 based on a CRISPR-Cas13a\/Cas12a system","volume":"258","author":"Tan","year":"2024","journal-title":"Biosensors & Bioelectronics"},{"issue":"7483","key":"10.1016\/j.pharmthera.2026.109069_bb0440","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nature12986","article-title":"The multilayered complexity of ceRNA crosstalk and competition","volume":"505","author":"Tay","year":"2014","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.pharmthera.2026.109069_bb0445","doi-asserted-by":"crossref","first-page":"6845","DOI":"10.1093\/nar\/gkr330","article-title":"Experimental strategies for microRNA target identification","volume":"39","author":"Thomson","year":"2011","journal-title":"Nucleic Acids Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109069_bb0450","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/nrg.2016.20","article-title":"Endogenous microRNA sponges: evidence and controversy","volume":"17","author":"Thomson","year":"2016","journal-title":"Nature Reviews. Genetics"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0455","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s42003-022-03539-x","article-title":"MALAT1-dependent hsa_circ_0076611 regulates translation rate in triple-negative breast cancer","volume":"5","author":"Turco","year":"2022","journal-title":"Communications Biology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109069_bb0465","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043822","article-title":"cRNAsp12 web server for the prediction of circular RNA secondary structures and stabilities","volume":"24","author":"Wang","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109069_bb0475","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1007\/s10528-024-10783-9","article-title":"CircRNA (circ)_0007823 contributes to triple-negative breast cancer progression and cisplatin resistance via the miR-182-5p\/FOXO1 pathway","volume":"63","author":"Wang","year":"2025","journal-title":"Biochemical Genetics"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109069_bb0480","first-page":"743","article-title":"Comprehensive circular RNA profiling reveals the regulatory role of the circRNA-000911\/miR-449a pathway in breast carcinogenesis","volume":"52","author":"Wang","year":"2018","journal-title":"International Journal of Oncology"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0485","doi-asserted-by":"crossref","first-page":"011","DOI":"10.2217\/epi-2018-0111","article-title":"Circular RNA expression in exosomes derived from breast cancer cells and patients","volume":"11","author":"Wang","year":"2019","journal-title":"Epigenomics"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0495","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2424515","article-title":"Hsa_circRNA_000166 accelerates breast cancer progression via the regulation of the miR-326\/ELK1 and miR-330-5p\/ELK1 axes","volume":"56","author":"Wang","year":"2024","journal-title":"Annals of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109069_bb0500","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1080\/08916934.2021.1931843","article-title":"Dysregulation of tumour microenvironment driven by circ-TPGS2\/miR-7\/TRAF6\/NF-kappaB axis facilitates breast cancer cell motility","volume":"54","author":"Wang","year":"2021","journal-title":"Autoimmunity"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109069_bb0505","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s13353-024-00840-9","article-title":"Peptidylprolyl isomerase D circular RNA sensitizes breast cancer to trastuzumab through remodeling HER2 N4-acetylcytidine modification","volume":"65","author":"Wang","year":"2024","journal-title":"Journal of Applied Genetics"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102896","article-title":"The novel beta-TrCP protein isoform hidden in circular RNA confers trastuzumab resistance in HER2-positive breast cancer","volume":"67","author":"Wang","year":"2023","journal-title":"Redox Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0515","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12672-023-00679-2","article-title":"Myc derived circRNA promotes triple-negative breast cancer progression via reprogramming fatty acid metabolism","volume":"14","author":"Wang","year":"2023","journal-title":"Discover Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0520","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13045-022-01345-w","article-title":"CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR","volume":"15","author":"Wang","year":"2022","journal-title":"Journal of Hematology & Oncology"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109069_bb0525","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s41419-022-05246-1","article-title":"CircSEMA4B inhibits the progression of breast cancer by encoding a novel protein SEMA4B-211aa and regulating AKT phosphorylation","volume":"13","author":"Wang","year":"2022","journal-title":"Cell Death & Disease"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0530","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12943-021-01383-x","article-title":"The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC","volume":"20","author":"Wang","year":"2021","journal-title":"Molecular Cancer"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109069_bb0535","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41419-021-03684-x","article-title":"Up-regulated circBACH2 contributes to cell proliferation, invasion, and migration of triple-negative breast cancer","volume":"12","author":"Wang","year":"2021","journal-title":"Cell Death & Disease"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109069_bb0540","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ccell.2022.05.005","article-title":"Redefining breast cancer subtypes to guide treatment prioritization and maximize response: predictive biomarkers across 10 cancer therapies","volume":"40","author":"Wolf","year":"2022","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109069_bb0545","article-title":"Circ_0000511 accelerates the proliferation, migration and invasion, and restrains the apoptosis of breast cancer cells through the miR-326\/TAZ axis","volume":"58","author":"Wu","year":"2021","journal-title":"International Journal of Oncology"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0550","article-title":"circWWC3 enhances the progression of triple-negative breast cancer by interacting with vimentin to regulate the secretion of CSF2","volume":"16","author":"Wu","year":"2025","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217823","article-title":"Therapeutic targeting of circTNK2 with nanoparticles restores tamoxifen sensitivity and enhances NK cell-mediated immunity in ER-positive breast cancer","volume":"627","author":"Wu","year":"2025","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216508","article-title":"A novel axis of circKIF4A-miR-637-STAT3 promotes brain metastasis in triple-negative breast cancer","volume":"581","author":"Wu","year":"2024","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0565","article-title":"Circular RNA circ-MMP11 contributes to lapatinib resistance of breast cancer cells by regulating the miR-153-3p\/ANLN axis","volume":"11","author":"Wu","year":"2021","journal-title":"Frontiers in Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0570","doi-asserted-by":"crossref","first-page":"12351","DOI":"10.1038\/s41598-025-96868-w","article-title":"CircSCD1 inhibits ferroptosis in breast cancer through stabilizing SCD1 protein via deubiquitinase OTUB1","volume":"15","author":"Wu","year":"2025","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0575","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13058-023-01672-x","article-title":"Chemotherapy-induced exosomal circBACH1 promotes breast cancer resistance and stemness via miR-217\/G3BP2 signaling pathway","volume":"25","author":"Xia","year":"2023","journal-title":"Breast Cancer Research"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217734","article-title":"Isoliquiritigenin reduces brain metastasis by circNAV3-ST6GALNAC5-EGFR axis in triple-negative breast cancer","volume":"624","author":"Xie","year":"2025","journal-title":"Cancer Letters"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0585","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41420-021-00604-y","article-title":"CircRNA circ-PDCD11 promotes triple-negative breast cancer progression via enhancing aerobic glycolysis","volume":"7","author":"Xing","year":"2021","journal-title":"Cell Death Discov"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109069_bb0590","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41419-024-06527-7","article-title":"Hsa_circ_0007990 promotes breast cancer growth via inhibiting YBX1 protein degradation to activate E2F1 transcription","volume":"15","author":"Xu","year":"2024","journal-title":"Cell Death & Disease"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109069_bb0595","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1158\/0008-5472.CAN-23-1899","article-title":"CircMMP2(6,7) cooperates with \u03b2-catenin and PRMT5 to disrupt bone homeostasis and promote breast cancer bone metastasis","volume":"84","author":"Xu","year":"2024","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0600","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12943-021-01394-8","article-title":"Circular RNA circIKBKB promotes breast cancer bone metastasis through sustaining NF-kappaB\/bone remodeling factors signaling","volume":"20","author":"Xu","year":"2021","journal-title":"Molecular Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0605","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12943-022-01567-z","article-title":"Hypoxia-induced circWSB1 promotes breast cancer progression through destabilizing p53 by interacting with USP10","volume":"21","author":"Yang","year":"2022","journal-title":"Molecular Cancer"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109069_bb0610","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41419-021-03680-1","article-title":"Tumor-derived exosomal circPSMA1 facilitates the tumorigenesis, metastasis, and migration in triple-negative breast cancer (TNBC) through miR-637\/Akt1\/beta-catenin (cyclin D1) axis","volume":"12","author":"Yang","year":"2021","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0615","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.omtn.2019.07.023","article-title":"circFBXW7 inhibits malignant progression by sponging miR-197-3p and encoding a 185-aa protein in triple-negative breast cancer","volume":"18","author":"Ye","year":"2019","journal-title":"Molecular Therapy - Nucleic Acids"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0620","article-title":"A novel peptide MIB1-223aa encoded by exosomal circMIB1 from cancer-associated fibroblasts drives triple-negative breast cancer metastasis and stemness via stabilizing MIB1 to activate Notch signaling","author":"Ye","year":"2025","journal-title":"Journal of Advanced Research"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109069_bb0625","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41419-023-05986-8","article-title":"Cancer-associated fibroblasts facilitate breast cancer progression through exosomal circTBPL1-mediated intercellular communication","volume":"14","author":"Ye","year":"2023","journal-title":"Cell Death & Disease"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0630","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cca.2017.10.011","article-title":"Circulating circular RNA hsa_circ_0001785 acts as a diagnostic biomarker for breast cancer detection","volume":"487","author":"Yin","year":"2018","journal-title":"Clinica Chimica Acta"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109069_bb0635","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/CAD.0000000000001264","article-title":"Knockdown of circ_0102273 inhibits the proliferation, metastasis and glycolysis of breast cancer through miR-1236-3p\/PFKFB3 axis","volume":"33","author":"Yu","year":"2022","journal-title":"Anti-Cancer Drugs"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109069_bb0640","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/1759-7714.13475","article-title":"Circ-RNF111 contributes to paclitaxel resistance in breast cancer by elevating E2F3 expression via miR-140-5p","volume":"11","author":"Zang","year":"2020","journal-title":"Thorac Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0645","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41420-021-00506-z","article-title":"Carcinoma-associated fibroblasts derived exosomes modulate breast cancer cell stemness through exonic circHIF1A by miR-580-5p in hypoxic stress","volume":"7","author":"Zhan","year":"2021","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0665","article-title":"CircEPSTI1 promotes the proliferation of HER2-positive breast cancer cells via circEPSTI1\/miR-145\/ERBB3 axis","volume":"2022","author":"Zhang","year":"2022","journal-title":"Journal of Oncology"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216907","article-title":"circLIFR-007 reduces liver metastasis via promoting hnRNPA1 nuclear export and YAP phosphorylation in breast cancer","volume":"592","author":"Zhang","year":"2024","journal-title":"Cancer Letters"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109069_bb0680","first-page":"500","article-title":"Microarray profile of circular RNAs identifies hsa_circ_0001583 as a new circular RNA biomarker for breast cancer: a retrospective study","volume":"24","author":"Zheng","year":"2022","journal-title":"Cell Journal"},{"key":"10.1016\/j.pharmthera.2026.109069_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.176221","article-title":"circNFIB decreases synthesis of arachidonic acid and inhibits breast tumor growth and metastasis","volume":"963","author":"Zhong","year":"2024","journal-title":"European Journal of Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109069_bb0690","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/s12935-021-02088-3","article-title":"CircFBXL5 promotes the 5-FU resistance of breast cancer via modulating miR-216b\/HMGA2 axis","volume":"21","author":"Zhu","year":"2021","journal-title":"Cancer Cell International"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109069_bb0695","doi-asserted-by":"crossref","first-page":"e1763","DOI":"10.1002\/ctm2.1763","article-title":"Exosomal circ-0100519 promotes breast cancer progression via inducing M2 macrophage polarisation by USP7\/NRF2 axis","volume":"14","author":"Zhuang","year":"2024","journal-title":"Clinical and Translational Medicine"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826000963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826000963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:28:55Z","timestamp":1785907735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725826000963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":132,"alternative-id":["S0163725826000963"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109069","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The CircRNA\/miRNA axis in breast cancer: From molecular mechanisms to clinical translation","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109069"}}